Rheumatoid Arthritis Drugs Market Report 2026

Rheumatoid Arthritis Drugs Market Overview

• Rheumatoid Arthritis Drugs market size has reached to $60.1 billion in 2025 • Expected to grow to $67.49 billion in 2030 at a compound annual growth rate (CAGR) of 2.5% • Growth Driver: Rising Elderly Population Fuels Expansion Of The Rheumatoid Arthritis Drugs Market • Market Trend: Innovations In Methotrexate Injection Enhance Treatment Flexibility And Safety In Rheumatoid Arthritis • North America was the largest region and fastest growing region.

What Is Covered Under Rheumatoid Arthritis Drugs Market?

Rheumatoid arthritis drugs refer to drugs given for the treatment of an autoimmune disease, which has symptoms like inflammation of the tissues around the joints. These medications minimize permanent harm to the joints and other tissues while slowing the progression of rheumatoid arthritis. The main types of rheumatoid arthritis drugs are nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), biologic response modifiers (BRMs) and other drug types. Nonsteroidal anti-inflammatory drugs (NSAIDs) refer to a class of drugs that are used to treat inflammation, fever, and other inflammatory conditions. It avoids many of the adverse effects of steroids. The different route of administration include oral, parenteral, topical and other route of administration. The rheumatoid arthritis drugs distribution channels include hospital pharmacy, retail pharmacy and online pharmacy.

What Is The Rheumatoid Arthritis Drugs Market Growth Forecast?

The rheumatoid arthritis drugs market size is expected to see steady growth in the next few years. It will grow to $67.49 billion in 2030 at a compound annual growth rate (CAGR) of 2.5%. The growth in the forecast period can be attributed to growing demand for biologics and BRMs, increasing uptake of biosimilars, advancement in precision medicine, expansion of online pharmacy channels, rising geriatric population. Major trends in the forecast period include expansion of biologic and targeted therapies, growing adoption of early and aggressive treatment strategies, increasing use of combination drug regimens, rising focus on personalized treatment protocols, growth of biosimilars in rheumatoid arthritis care.

Global Rheumatoid Arthritis Drugs Market Segmentation

1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Response Modifiers (BRMs), Other Drug Types 2) By Route Of Administration: Oral, Parenteral, Topical, Other Route Of Administrations 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Indomethacin 2) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone 3) By Disease-Modifying Antirheumatic Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide 4) By Biologic Response Modifiers: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, B-cell Inhibitors 5) By Other Drug Types: Janus Kinase Inhibitors, Other Novel Therapies

What Is The Driver Of The Rheumatoid Arthritis Drugs Market?

The growing elderly population is expected to propel the growth of the rheumatoid arthritis drugs market going forward. The elderly population refers to individuals aged 65 years or older, who increasingly constitute a larger share of the general population. This demographic shift is primarily driven by longer life expectancy and declining fertility rates, resulting in a larger proportion of older adults globally. Since rheumatoid arthritis is more prevalent among older individuals, this increase in the elderly cohort drives greater demand for effective RA therapies, especially newer agents like JAK inhibitors and targeted synthetic DMARDs which may be better tolerated in older patients. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based Nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. Therefore, the growing elderly population is driving the growth of the rheumatoid arthritis drugs industry.

Key Players In The Global Rheumatoid Arthritis Drugs Market

Major companies operating in the rheumatoid arthritis drugs market are Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Regeneron Pharmaceuticals Inc., Galapagos NV, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A., Roche Holding AG, Mallinckrodt Pharmaceuticals, AstraZeneca PLC, Bayer AG

Global Rheumatoid Arthritis Drugs Market Trends and Insights

Major companies operating in the rheumatoid arthritis drugs market are focusing on developing advanced solutions, such as flexible-dose methotrexate injections, to enhance treatment efficacy, improve patient safety, and offer convenient administration options. Flexible-dose methotrexate injections provide various strengths tailored for adult patients with active RA, enabling individualized therapy and better management of disease activity. For instance, in December 2023, China Medical System Holdings Limited, a China-based investment holding company principally engaged in the production of medicines, had its New Drug Application for an additional rheumatoid arthritis indication of Methotrexate Injection accepted by the National Medical Products Administration. Designed for adult RA patients, the product has demonstrated in clinical trials that it is not inferior to methotrexate tablets, showing a trend of earlier and improved efficacy while reducing gastrointestinal side effects. The injection has already been approved for severe psoriasis in China and is marketed in over 40 countries, reflecting its established clinical utility and global reach.

What Are Latest Mergers And Acquisitions In The Rheumatoid Arthritis Drugs Market?

In October 2023, Amgen PLC, a US-based biotechnology company, acquired Horizon Therapeutic Plc for $27.8 billion. This acquisition strengthens Amgen’s inflammation portfolio by adding first-in-class, early-in-lifecycle medicines to treat rare inflammatory diseases. Horizon Therapeutic PLC, is an Ireland-based biopharmaceutical company that provides treatments for focal segmental glomerulosclerosis, kidney transplant rejection, and rheumatoid arthritis drugs.

Regional Insights

North America was the largest region in the rheumatoid arthritis drugs market in 2025.North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Rheumatoid Arthritis Drugs Market?

The rheumatoid arthritis drugs market consists of sales of products like abatacept, aceclofenac and adalimumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rheumatoid Arthritis Drugs Market Report 2026?

The rheumatoid arthritis drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatoid arthritis drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.